SMMT Summit Therapeutics plc - Ameri

11.64
+0.29  (3%)
Previous Close 11.35
Open 11.32
Price To book 0.00
Market Cap 144.11M
Shares 12,381,000
Volume 1,942
Short Ratio 8.96
Av. Daily Volume 8,822

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
Ridinilazole
C. difficile infection (CDI)
Phase 2 completion of enrollment announced May 15, 2017. 24-week data due 1Q 2018.
Ezutromid
Duchenne muscular dystrophy

Latest News

  1. Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q1, 2018 By the Numbers : June 22, 2017
  2. Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
  3. Summit Therapeutics to Participate in JMP Securities Life Sciences Conference
  4. Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
  5. Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017
  6. Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017
  7. Summit Announces Key Appointments to Strengthen Research and Development Team
  8. Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
  9. Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
  10. Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
  11. Summit Therapeutics to Present at the Needham Healthcare Conference
  12. Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
  13. Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
  14. Glaxo Files for Label Expansion of Influenza Vaccine in US
  15. Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
  16. J&J Presents Positive Phase III Data on Psoriasis Candidate
  17. Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat